CASP3 and hepatocellular carcinoma: However, compared with wild-type cells, bortezomib-induced caspase-3 activity, the percentage of cell death, and the expression of apoptosis-associated proteins appeared to be failed to increase in response to in bortezomib-resistant HCC cells.